in patients with congestive heart failure Hemodynamic and neurohumoral effects of continuous infusion of levosimendan

J. Am. Coll. Cardiol. 2000;36;1903-1912 Group Lehtonen, Veselin Mitrovic, Olof Nyquist, Willem J. Remme, on behalf of the Study Markku S. Nieminen, Juha Akkila, Gerd Hasenfuss, Franz X. Kleber, Lasse A.in patients with congestive heart failure Hemodynamic and neurohumoral effects of continuous infusion of levosimendanThis information is current as of December 30, 2011 http://content.onlinejacc.org/cgi/content/full/36/6/1903 located on the World Wide Web at: The online version of this article, along with updated information and services, isDownloaded from content.onlinejacc.org

[1]  L. Toivonen,et al.  Effects of Levosimendan on Cardiac Arrhythmia: Electrophysiologic and Ambulatory Electrocardiographic Findings in Phase II and Phase III Clinical Studies in Cardiac Failure , 1999 .

[2]  G. Hasenfuss,et al.  Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. , 1998, Circulation.

[3]  M. Sunagawa,et al.  The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  M. Sunagawa,et al.  Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. , 1997, European journal of pharmacology.

[5]  P. Kaheinen,et al.  The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. , 1997, Cardiovascular research.

[6]  K. Någren,et al.  Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers , 1997, Clinical pharmacology and therapeutics.

[7]  A. Skene,et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.

[8]  C. Holubarsch.  New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. , 1997, Cardiology.

[9]  N. Alpert,et al.  Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. , 1996, Circulation.

[10]  J. Cohn,et al.  The management of chronic heart failure. , 1996, The New England journal of medicine.

[11]  L. Donck.  Calcium‐Sensitizing Drugs: Positive Inotropy by Enhanced Sensitivity of the Contractile Apparatus to Calcium , 1996 .

[12]  J. Levijoki,et al.  Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. , 1995, Journal of molecular and cellular cardiology.

[13]  J. Levijoki,et al.  Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation , 1995, Journal of cardiovascular pharmacology.

[14]  N. Alpert,et al.  Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. , 1995, Journal of cardiovascular pharmacology.

[15]  N. Kalkkinen,et al.  Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. , 1994, The Journal of biological chemistry.

[16]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[17]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[18]  P. Merlet,et al.  Physiologic Assessment of Milrinone Therapy in Severe Heart Failure Patients , 1991, Journal of Cardiovascular Pharmacology.

[19]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[20]  M. Packer,et al.  Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. , 1985, Circulation.